Automated machine learning to predict the co-occurrence of isocitrate dehydrogenase mutations and O6 -methylguanine-DNA methyltransferase promoter methylation in patients with gliomas
- PMID: 33393131
- DOI: 10.1002/jmri.27498
Automated machine learning to predict the co-occurrence of isocitrate dehydrogenase mutations and O6 -methylguanine-DNA methyltransferase promoter methylation in patients with gliomas
Abstract
Combining isocitrate dehydrogenase mutation (IDHmut) with O6 -methylguanine-DNA methyltransferase promoter methylation (MGMTmet) has been identified as a critical prognostic molecular marker for gliomas. The aim of this study was to determine the ability of glioma radiomics features from magnetic resonance imaging (MRI) to predict the co-occurrence of IDHmut and MGMTmet by applying the tree-based pipeline optimization tool (TPOT), an automated machine learning (autoML) approach. This was a retrospective study, in which 162 patients with gliomas were evaluated, including 58 patients with co-occurrence of IDHmut and MGMTmet and 104 patients with other status comprising: IDH wildtype and MGMT unmethylated (n = 67), IDH wildtype and MGMTmet (n = 36), and IDHmut and MGMT unmethylated (n = 1). Three-dimensional (3D) T1-weighted images, gadolinium-enhanced 3D T1-weighted images (Gd-3DT1WI), T2-weighted images, and fluid-attenuated inversion recovery (FLAIR) images acquired at 3.0 T were used. Radiomics features were extracted from FLAIR and Gd-3DT1WI images. The TPOT was employed to generate the best machine learning pipeline, which contains both feature selector and classifier, based on input feature sets. A 4-fold cross-validation was used to evaluate the performance of automatically generated models. For each iteration, the training set included 121 subjects, while the test set included 41 subjects. Student's t-test or a chi-square test was applied on different clinical characteristics between two groups. Sensitivity, specificity, accuracy, kappa score, and AUC were used to evaluate the performance of TPOT-generated models. Finally, we compared the above metrics of TPOT-generated models to identify the best-performing model. Patients' ages and grades between two groups were significantly different (p = 0.002 and p = 0.000, respectively). The 4-fold cross-validation showed that gradient boosting classifier trained on shape and textual features from the Laplacian-of-Gaussian-filtered Gd-3DT1 achieved the best performance (average sensitivity = 81.1%, average specificity = 94%, average accuracy = 89.4%, average kappa score = 0.76, average AUC = 0.951). Using autoML based on radiomics features from MRI, a high discriminatory accuracy was achieved for predicting co-occurrence of IDHmut and MGMTmet in gliomas. LEVEL OF EVIDENCE: 3 TECHNICAL EFFICACY STAGE: 3.
Keywords: O6-methylguanine-DNA methyltransferase promoter methylation; automated machine learning; glioma; isocitrate dehydrogenase mutation; tree-based optimization tool.
© 2021 International Society for Magnetic Resonance in Medicine.
Similar articles
-
Automated machine learning based on radiomics features predicts H3 K27M mutation in midline gliomas of the brain.Neuro Oncol. 2020 Mar 5;22(3):393-401. doi: 10.1093/neuonc/noz184. Neuro Oncol. 2020. PMID: 31563963 Free PMC article.
-
The diagnostic value of ADC histogram and direct ADC measurements for coexisting isocitrate dehydrogenase mutation and O6-methylguanine-DNA methyltransferase promoter methylation in glioma.Front Neurosci. 2023 Jan 11;16:1099019. doi: 10.3389/fnins.2022.1099019. eCollection 2022. Front Neurosci. 2023. PMID: 36711137 Free PMC article.
-
Radiomic study on preoperative multi-modal magnetic resonance images identifies IDH-mutant TERT promoter-mutant gliomas.Cancer Med. 2023 Feb;12(3):2524-2537. doi: 10.1002/cam4.5097. Epub 2022 Sep 29. Cancer Med. 2023. PMID: 36176070 Free PMC article.
-
The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.Neurosurg Focus. 2019 Dec 1;47(6):E13. doi: 10.3171/2019.9.FOCUS19660. Neurosurg Focus. 2019. PMID: 31786548
-
Machine Learning for the Prediction of Molecular Markers in Glioma on Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis.Neurosurgery. 2021 Jun 15;89(1):31-44. doi: 10.1093/neuros/nyab103. Neurosurgery. 2021. PMID: 33826716
Cited by
-
Predicting postoperative recurrence and survival in glioma patients using enhanced MRI-based delta habitat radiomics: an 8-year retrospective pilot study.World J Surg Oncol. 2025 Mar 28;23(1):104. doi: 10.1186/s12957-025-03760-y. World J Surg Oncol. 2025. PMID: 40155892 Free PMC article.
-
From pixels to prognosis: leveraging radiomics and machine learning to predict IDH1 genotype in gliomas.Neurosurg Rev. 2025 Apr 29;48(1):396. doi: 10.1007/s10143-025-03515-z. Neurosurg Rev. 2025. PMID: 40299088 Free PMC article.
-
Artificial Intelligence Imaging for Predicting High-risk Molecular Markers of Gliomas.Clin Neuroradiol. 2024 Mar;34(1):33-43. doi: 10.1007/s00062-023-01375-y. Epub 2024 Jan 26. Clin Neuroradiol. 2024. PMID: 38277059 Review.
-
Non-Invasive Prediction of Survival Time of Midline Glioma Patients Using Machine Learning on Multiparametric MRI Radiomics Features.Front Neurol. 2022 May 2;13:866274. doi: 10.3389/fneur.2022.866274. eCollection 2022. Front Neurol. 2022. PMID: 35585843 Free PMC article.
-
AI-driven estimation of O6 methylguanine-DNA-methyltransferase (MGMT) promoter methylation in glioblastoma patients: a systematic review with bias analysis.J Cancer Res Clin Oncol. 2024 Jan 31;150(2):57. doi: 10.1007/s00432-023-05566-5. J Cancer Res Clin Oncol. 2024. PMID: 38291266 Free PMC article.
References
-
- Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392:432-46.
-
- Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, ESMO Guidelines Working Group. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 (Suppl 3):iii93-iii101.
-
- Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-73.
-
- Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
-
- Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol. 2012;14 (Suppl 4):iv100-8.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials